ASCO GU 2021: Molecular Determinants Associated with Long-Term Response to Apalutamide in nmCRPC and Final Results from the ACIS Phase 3 Study – Discussion

(UroToday.com) Following presentations by Dr. Felix Feng assessing molecular determinants of response to apalutamide in patients with non-metastatic prostate cancer and by Dr. Dana Rathkopf looking at the ACIS trial combining apalutamide and abiraterone acetate in patients with newly diagnosed metastatic castration-resistant prostate cancer, Dr. Joshi Alumkal provided a discussion of these data in the Oral […]

ASCO GU 2021: Australia and New Zealand Outcomes of High-Dose Chemotherapy and Stem Cell Transplantation for Relapsed or Refractory Germ Cell Tumors from 1999 to 2019: Multicenter Registry-Based Study with ABMTRR

(UroToday.com) The treatment of germ cell tumors that relapse after or are refractory to platinum-based chemotherapy can include high dose chemotherapy (HDCT) with autologous stem-cell transplant (ASCT). Multiple cohorts from North America and Europe suggest that 5-year overall survival with HDCT ranges is between 48% and 65%. In this abstract, the authors conducted a retrospective and […]

ASCO GU 2021: Longer Follow-up Data of Circulating miR371a-3p Expression Across the Spectrum of Germ Cell Tumors

(UroToday.com) In a prior publication, the authors of this abstract published results confirming plasma expression of the microRNA 371a-3p (miR371) can be utilized as a sensitive and specific marker of active germ cell malignancy in patients. In this abstract, Dr. Lucia Nappi and colleagues present updated follow-up data with miR371 expression data to further define the […]

ASCO GU 2021: Prediction Model for Brain Metastasis in Patients with Metastatic Germ-Cell Tumors Accounting for Size of Pulmonary Metastases

(UroToday.com) The presence of brain metastases stratifies metastatic germ cell tumors as poor risk and is an independent adverse prognostic factor that can lead to treatment complications and failure. Brain imaging is not necessarily performed for staging imaging unless neurologic symptoms are present. In this abstract, the authors aimed to create a predictive model using certain […]

Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer A Secondary Analysis of a Randomized Clinical Trial

KEY POINTSQuestion Are bone metastatic burden and site associated with survival benefit from the addition of prostate radiotherapy (RT) to standard-of-care systemic therapy in newly diagnosed metastatic prostate cancer? Findings This exploratory analysis of 1939 participants in a randomized clinical trial shows that survival benefit following prostate RT gradually diminished with increasing bone metastasis number, with survival […]

X